BRIEF-AstraZeneca says fostamatinib did not meet study goal

LONDON Thu Dec 13, 2012 2:29am EST

Related Topics

LONDON Dec 13 (Reuters) - AstraZeneca PLC : * Top-line results of oskira-4 phase iib study of fostamatinib as a monotherapy

for rheumatoid arthritis * Did not meet second primary goal * All fostamatinib monotherapy doses were inferior to adalimumab monotherapy at

week 24 based on das28

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.